Is Novo Nordisk (NYSE:NVO) a full-fledged pharmaceutical company, or does it fall into that "specialty pharmaceutical" niche? Will the company succeed in expanding beyond diabetes and very specialized hormone/protein therapies? Does anybody care so long as the company delivers double-digit revenue growth and returns on capital that approach 40%?

TUTORIAL: Stock Basics

The Strong Get Stronger in Q1
While some analysts seem to be fretting a bit about a "slowdown" in the insulin business for Novo Nordisk, the fact remains that this is one of the fastest-growing major pharmaceutical companies on the planet. Total revenue rose 15% this quarter, with the diabetes franchise growing 16% and the biopharmaceuticals business up 10%. Within diabetes, insulins grew 8% due to continued growth of the analog platform, while Victoza showed nearly 200% growth and delivered over $200 million in revenue on its way to blockbuster status.

Profitability also improved this quarter. Gross margin slid a bit as the company could not completely offset a drag from foreign currency, but the loss was limited to 20 basis points. Operating income grew 24%, though, as sales, administrative and R&D expenses all grew by mid-single-digit amounts. Although the R&D spend looked a bit light this quarter, it looks like more of a timing issue than any sort of philosophical change.

The Diabetes Fortress Still Strong
Novo Nordisk is demonstrating why diabetes is a great franchise for drug companies; the products have to be used over and over again and the reimbursement is strong. Although the company lost some insulin analog share in the United States because of a few managed care contracts that went to Lilly (NYSE:LLY), there is nothing going on in the market that suggests the company is really losing any meaningful ground to Lilly or Sanofi-Aventis (NYSE:SNY) in this market. Likewise, the company is clearly having no problems competing with Merck's (NYSE:MRK) Januvia or Bristol-Myers' (NYSE:BMY) Onglyza.

At the same time, the FDA and would-be competitor missteps are limiting competition. The FDA rejected new insulin formulations from Biodel (Nasdaq:BIOD) and MannKind (Nasdaq:MNKD), and it is unclear if either of these companies will succeed in securing approvals for their oral and inhaled insulin products. Elsewhere, the prospects for Victoza got a big boost from the FDA setback with Bydureon, an anti-diabetes medication that Lilly hopes to co-market as a follow-up to the successful GLP-1 drug Byetta.

An Interesting, but Mixed, Pipeline
As is often the case, Novo had a mix of good and disappointing news on its pipeline. The company is abandoning an oral rapid-acting insulin, while still working on a longer-acting formulation. Data on a would-be rival to Sanofi's Lantus appears to be viable for approval and competitive launch. The company advanced two compounds into Phase 2 studies for rheumatoid arthritis and Crohn's disease (and these are potentially valuable expansions into antibody therapy), but also reported that trials for new applications for Factor 7a and 13 failed.

The Bottom Line
Novo Nordisk clearly stands out from Astra Zeneca (NYSE:AZN), Novartis (NYSE:NVS) and Sanofi-Aventis as a great growth-oriented European pharmaceutical company. It also stands out in terms of its valuation. For investors who doubt just how much investors hate uncertainty and will reward reliable growth (with moderate competitive threats), Novo Nordisk is a great example.

Even allowing for strong ongoing growth in free cash flow and a generous discount rate, Novo Nordisk shares do not look cheap enough today. Though this would be a fantastic stock to buy on a pullback or market correction, it just seems too expensive today. (For related reading, also take a look at Pharmaceutical Sector: Does The FDA Help Or Harm?)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  3. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  9. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!